Reversal of loss of bone mass in old mice treated with mefloquine

Rafael Pacheco-Costa, Hannah M. Davis, Emily G. Atkinson, Julian E. Dilley, Innocent Byiringiro, Mohammad W. Aref, Matthew Allen, Teresita Bellido, Lilian Plotkin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aging is accompanied by imbalanced bone remodeling, elevated osteocyte apoptosis, and decreased bone mass and mechanical properties; and improved pharmacologic approaches to counteract bone deterioration with aging are needed. We examined herein the effect of mefloquine, a drug used to treat malaria and systemic lupus erythematosus and shown to ameliorate bone loss in glucocorticoid-treated patients, on bone mass and mechanical properties in young and old mice. Young 3.5-month-old and old 21-month-old female C57BL/6 mice received daily injections of 5 mg/kg/day mefloquine for 14 days. Aging resulted in the expected changes in bone volume and mechanical properties. In old mice mefloquine administration reversed the lower vertebral cancellous bone volume and bone formation; and had modest effects on cortical bone volume, thickness, and moment of inertia. Mefloquine administration did not change the levels of the circulating bone formation markers P1NP or alkaline phosphatase, whereas levels of the resorption marker CTX showed trends towards increase with mefloquine treatment. In addition, and as expected, aging bones exhibited an accumulation of active caspase3-expressing osteocytes and higher expression of apoptosis-related genes compared to young mice, which were not altered by mefloquine administration at either age. In young animals, mefloquine induced higher periosteal bone formation, but lower endocortical bone formation. Further, osteoclast numbers were higher on the endocortical bone surface and circulating CTX levels were increased, in mefloquine- compared to vehicle-treated young mice. Consistent with this, addition of mefloquine to bone marrow cells isolated from young mice led to increased osteoclastic gene expression and a tendency towards increased osteoclast numbers in vitro. Taken together our findings identify the age and bone-site specific skeletal effects of mefloquine. Further, our results highlight a beneficial effect of mefloquine administration on vertebral cancellous bone mass in old animals, raising the possibility of using this pharmacologic inhibitor to preserve skeletal health with aging.

Original languageEnglish (US)
Pages (from-to)22-31
Number of pages10
JournalBone
Volume114
DOIs
StatePublished - Sep 1 2018

Fingerprint

Mefloquine
Bone and Bones
Osteogenesis
Osteocytes
Osteoclasts
Apoptosis
Bone Remodeling
Inbred C57BL Mouse
Bone Marrow Cells
Systemic Lupus Erythematosus
Glucocorticoids
Malaria
Alkaline Phosphatase

Keywords

  • Aging
  • Cell/tissue signaling
  • Osteoclast
  • Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Pacheco-Costa, R., Davis, H. M., Atkinson, E. G., Dilley, J. E., Byiringiro, I., Aref, M. W., ... Plotkin, L. (2018). Reversal of loss of bone mass in old mice treated with mefloquine. Bone, 114, 22-31. https://doi.org/10.1016/j.bone.2018.06.002

Reversal of loss of bone mass in old mice treated with mefloquine. / Pacheco-Costa, Rafael; Davis, Hannah M.; Atkinson, Emily G.; Dilley, Julian E.; Byiringiro, Innocent; Aref, Mohammad W.; Allen, Matthew; Bellido, Teresita; Plotkin, Lilian.

In: Bone, Vol. 114, 01.09.2018, p. 22-31.

Research output: Contribution to journalArticle

Pacheco-Costa, R, Davis, HM, Atkinson, EG, Dilley, JE, Byiringiro, I, Aref, MW, Allen, M, Bellido, T & Plotkin, L 2018, 'Reversal of loss of bone mass in old mice treated with mefloquine', Bone, vol. 114, pp. 22-31. https://doi.org/10.1016/j.bone.2018.06.002
Pacheco-Costa R, Davis HM, Atkinson EG, Dilley JE, Byiringiro I, Aref MW et al. Reversal of loss of bone mass in old mice treated with mefloquine. Bone. 2018 Sep 1;114:22-31. https://doi.org/10.1016/j.bone.2018.06.002
Pacheco-Costa, Rafael ; Davis, Hannah M. ; Atkinson, Emily G. ; Dilley, Julian E. ; Byiringiro, Innocent ; Aref, Mohammad W. ; Allen, Matthew ; Bellido, Teresita ; Plotkin, Lilian. / Reversal of loss of bone mass in old mice treated with mefloquine. In: Bone. 2018 ; Vol. 114. pp. 22-31.
@article{eade694c95fa475bb30720bd0006c452,
title = "Reversal of loss of bone mass in old mice treated with mefloquine",
abstract = "Aging is accompanied by imbalanced bone remodeling, elevated osteocyte apoptosis, and decreased bone mass and mechanical properties; and improved pharmacologic approaches to counteract bone deterioration with aging are needed. We examined herein the effect of mefloquine, a drug used to treat malaria and systemic lupus erythematosus and shown to ameliorate bone loss in glucocorticoid-treated patients, on bone mass and mechanical properties in young and old mice. Young 3.5-month-old and old 21-month-old female C57BL/6 mice received daily injections of 5 mg/kg/day mefloquine for 14 days. Aging resulted in the expected changes in bone volume and mechanical properties. In old mice mefloquine administration reversed the lower vertebral cancellous bone volume and bone formation; and had modest effects on cortical bone volume, thickness, and moment of inertia. Mefloquine administration did not change the levels of the circulating bone formation markers P1NP or alkaline phosphatase, whereas levels of the resorption marker CTX showed trends towards increase with mefloquine treatment. In addition, and as expected, aging bones exhibited an accumulation of active caspase3-expressing osteocytes and higher expression of apoptosis-related genes compared to young mice, which were not altered by mefloquine administration at either age. In young animals, mefloquine induced higher periosteal bone formation, but lower endocortical bone formation. Further, osteoclast numbers were higher on the endocortical bone surface and circulating CTX levels were increased, in mefloquine- compared to vehicle-treated young mice. Consistent with this, addition of mefloquine to bone marrow cells isolated from young mice led to increased osteoclastic gene expression and a tendency towards increased osteoclast numbers in vitro. Taken together our findings identify the age and bone-site specific skeletal effects of mefloquine. Further, our results highlight a beneficial effect of mefloquine administration on vertebral cancellous bone mass in old animals, raising the possibility of using this pharmacologic inhibitor to preserve skeletal health with aging.",
keywords = "Aging, Cell/tissue signaling, Osteoclast, Therapeutics",
author = "Rafael Pacheco-Costa and Davis, {Hannah M.} and Atkinson, {Emily G.} and Dilley, {Julian E.} and Innocent Byiringiro and Aref, {Mohammad W.} and Matthew Allen and Teresita Bellido and Lilian Plotkin",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.bone.2018.06.002",
language = "English (US)",
volume = "114",
pages = "22--31",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Reversal of loss of bone mass in old mice treated with mefloquine

AU - Pacheco-Costa, Rafael

AU - Davis, Hannah M.

AU - Atkinson, Emily G.

AU - Dilley, Julian E.

AU - Byiringiro, Innocent

AU - Aref, Mohammad W.

AU - Allen, Matthew

AU - Bellido, Teresita

AU - Plotkin, Lilian

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Aging is accompanied by imbalanced bone remodeling, elevated osteocyte apoptosis, and decreased bone mass and mechanical properties; and improved pharmacologic approaches to counteract bone deterioration with aging are needed. We examined herein the effect of mefloquine, a drug used to treat malaria and systemic lupus erythematosus and shown to ameliorate bone loss in glucocorticoid-treated patients, on bone mass and mechanical properties in young and old mice. Young 3.5-month-old and old 21-month-old female C57BL/6 mice received daily injections of 5 mg/kg/day mefloquine for 14 days. Aging resulted in the expected changes in bone volume and mechanical properties. In old mice mefloquine administration reversed the lower vertebral cancellous bone volume and bone formation; and had modest effects on cortical bone volume, thickness, and moment of inertia. Mefloquine administration did not change the levels of the circulating bone formation markers P1NP or alkaline phosphatase, whereas levels of the resorption marker CTX showed trends towards increase with mefloquine treatment. In addition, and as expected, aging bones exhibited an accumulation of active caspase3-expressing osteocytes and higher expression of apoptosis-related genes compared to young mice, which were not altered by mefloquine administration at either age. In young animals, mefloquine induced higher periosteal bone formation, but lower endocortical bone formation. Further, osteoclast numbers were higher on the endocortical bone surface and circulating CTX levels were increased, in mefloquine- compared to vehicle-treated young mice. Consistent with this, addition of mefloquine to bone marrow cells isolated from young mice led to increased osteoclastic gene expression and a tendency towards increased osteoclast numbers in vitro. Taken together our findings identify the age and bone-site specific skeletal effects of mefloquine. Further, our results highlight a beneficial effect of mefloquine administration on vertebral cancellous bone mass in old animals, raising the possibility of using this pharmacologic inhibitor to preserve skeletal health with aging.

AB - Aging is accompanied by imbalanced bone remodeling, elevated osteocyte apoptosis, and decreased bone mass and mechanical properties; and improved pharmacologic approaches to counteract bone deterioration with aging are needed. We examined herein the effect of mefloquine, a drug used to treat malaria and systemic lupus erythematosus and shown to ameliorate bone loss in glucocorticoid-treated patients, on bone mass and mechanical properties in young and old mice. Young 3.5-month-old and old 21-month-old female C57BL/6 mice received daily injections of 5 mg/kg/day mefloquine for 14 days. Aging resulted in the expected changes in bone volume and mechanical properties. In old mice mefloquine administration reversed the lower vertebral cancellous bone volume and bone formation; and had modest effects on cortical bone volume, thickness, and moment of inertia. Mefloquine administration did not change the levels of the circulating bone formation markers P1NP or alkaline phosphatase, whereas levels of the resorption marker CTX showed trends towards increase with mefloquine treatment. In addition, and as expected, aging bones exhibited an accumulation of active caspase3-expressing osteocytes and higher expression of apoptosis-related genes compared to young mice, which were not altered by mefloquine administration at either age. In young animals, mefloquine induced higher periosteal bone formation, but lower endocortical bone formation. Further, osteoclast numbers were higher on the endocortical bone surface and circulating CTX levels were increased, in mefloquine- compared to vehicle-treated young mice. Consistent with this, addition of mefloquine to bone marrow cells isolated from young mice led to increased osteoclastic gene expression and a tendency towards increased osteoclast numbers in vitro. Taken together our findings identify the age and bone-site specific skeletal effects of mefloquine. Further, our results highlight a beneficial effect of mefloquine administration on vertebral cancellous bone mass in old animals, raising the possibility of using this pharmacologic inhibitor to preserve skeletal health with aging.

KW - Aging

KW - Cell/tissue signaling

KW - Osteoclast

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85048089274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048089274&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2018.06.002

DO - 10.1016/j.bone.2018.06.002

M3 - Article

VL - 114

SP - 22

EP - 31

JO - Bone

JF - Bone

SN - 8756-3282

ER -